Explore the innovative world of field studies with FluCamp, revolutionising clinical research by bringing trials closer to real-life scenarios.
hVIVO plc achieves milestone with £3.2 million hLAB contract, showcasing growth in laboratory services. Read about the company’s latest achievement here.
hVIVO pioneers infectious disease research with successful hMPV study.
hVIVO plc, a leading CRO specializing in infectious disease testing, announces a £2.7m virology lab contract with a US biotech client.
The importance of diversity in clinical trials cannot be overstated. Addressing gaps in representation is crucial for accurate and inclusive medical research.
hVIVO plc (LON: HVO) has successfully completed a pilot study for its hMPV challenge model, paving the way for new vaccines and antivirals.
hVIVO supports UK Health Security Agency’s advice on hand hygiene to combat seasonal illnesses. Learn more about their vital role in public health here.
Discover how hVIVO Group’s innovative approach to human challenge trials and infectious disease expertise has shaped the future of pharmaceutical research in 2024.
hVIVO secures £11.5 million contract to test RSV drug candidate, highlighting the importance of human challenge models in addressing infectious diseases.
Host response biomarkers to viral infections have significant potential in clinical applications, such as guiding diagnostic decisions, reducing unnecessary antibiotic use, and triggering infection control protocols or antiviral treatments. Research
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
